(Q36129105)

12 August 2017

1 reference

title

Keynote review: Medicinal chemistry strategies to CB1 cannabinoid receptor antagonists (English)

1 reference

12 August 2017

0 references

0 references

0 references

Jos H M Lange

1 reference

12 August 2017

Chris G Kruse

series ordinal

1 reference

12 August 2017

publication date

1 May 2005

1 reference

12 August 2017

1 reference

12 August 2017

1 reference

12 August 2017

1 reference

12 August 2017

page(s)

693-702

1 reference

Towards cannabinoid drugs--revisited.

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Endocannabinoid signaling in the brain

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

The endocannabinoid system: a general view and latest additions

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Structure of a cannabinoid receptor and functional expression of the cloned cDNA

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Molecular characterization of a peripheral receptor for cannabinoids

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

CB1 cannabinoid receptors and on-demand defense against excitotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

The endocannabinoid system and its therapeutic exploitation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Possible involvement of the endocannabinoid system in the actions of three clinically used drugs.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Cannabinoid physiology and pharmacology: 30 years of progress.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Pharmacology of cannabinoid CB1 and CB2 receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Cannabinoid receptors and immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Nonpsychotropic cannabinoid receptors regulate microglial cell migration.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

G protein-coupled endothelial receptor for atypical cannabinoid ligands modulates a Ca2+-dependent K+ current

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Pharmacophores for ligand recognition and activation/inactivation of the cannabinoid receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Therapeutic potential of cannabinoids in CNS disease

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

General Articles Cannabinoids: Mechanisms and Therapeutic Applications in the CNS

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Possible endocannabinoid control of colorectal cancer growth

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Towards cannabis and cannabinoid treatment of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

3-(1',1'-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Cannabinoids control spasticity and tremor in a multiple sclerosis model

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

The cannabinoid system and immune modulation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Pharmaceutical approaches to the treatment of obesity

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Evidence for an interaction between CB1 cannabinoid and melanocortin MCR-4 receptors in regulating food intake.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Ethanol, endocannabinoids, and the cannabinoidergic signaling system

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Cannabinoids and memory: animal studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

SR141716A, a cannabinoid CB1 receptor antagonist, improves memory in a delayed radial maze task

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Potentiation of penile erection and yawning responses to apomorphine by cannabinoid receptor antagonist in rats

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Antagonism of cannabinoid CB1 receptors in the paraventricular nucleus of male rats induces penile erection

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Evidence for presynaptic cannabinoid CB(1) receptor-mediated inhibition of noradrenaline release in the guinea pig lung

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Upregulation of CB1 receptors and agonist-stimulated [35S]GTPgammaS binding in the prefrontal cortex of depressed suicide victims

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

An Aromatic Microdomain at the Cannabinoid CB1 Receptor Constitutes an Agonist/Inverse Agonist Binding Region

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

The bioactive conformation of aminoalkylindoles at the cannabinoid CB1 and CB2 receptors: insights gained from (E)- and (Z)-naphthylidene indenes.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Synthesis and structure-activity relationships of amide and hydrazide analogues of the cannabinoid CB(1) receptor antagonist N-(piperidinyl)- 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716).

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2, 4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871)

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Synthesis, structure-activity relationship, and evaluation of SR141716 analogues: development of central cannabinoid receptor ligands with lower lipophilicity.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Inverse agonism and neutral antagonism at cannabinoid CB1 receptors

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Development of a 3D model for the human cannabinoid CB1 receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Homology model of the CB1 cannabinoid receptor: sites critical for nonclassical cannabinoid agonist interaction.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Membrane assembly of the cannabinoid receptor 1: impact of a long N-terminal tail

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Design, synthesis and biological activity of rigid cannabinoid CB1 receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Synthesis and characterization of NESS 0327: a novel putative antagonist of the CB1 cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Tricyclic pyrazoles. Part 1: synthesis and biological evaluation of novel 1,4-dihydroindeno[1,2-c]pyrazol-based ligands for CB1and CB2 cannabinoid receptors.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Bioisosterism: a useful strategy for molecular modification and drug design

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Potent imidazole and triazole CB1 receptor antagonists related to SR141716.

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Synthesis and activity of 4,5-diarylimidazoles as human CB1 receptor inverse agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Synthesis and SAR of 5,6-diarylpyridines as human CB1 inverse agonists

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

Discovery of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1h-1,2,4-triazole, a novel in vivo cannabinoid antagonist containing a 1,2,4-triazole motif

1 reference

https://api.crossref.org/works/10.1016%2FS1359-6446%2805%2903427-6

7 January 2021

10.1016/S1359-6446(05)03427-6

Identifiers

DOI

1 reference

12 August 2017

1 reference